Valuation: Starpharma Holdings Limited

Market Cap 314M 219M 192M 179M 165M 308M 20.91B 2.12B 831M 10.37B 822M 804M 35.84B P/E 2026 *
-0.93x
P/E 2027 * -
Enterprise Value 303M 211M 186M 173M 159M 298M 20.19B 2.05B 802M 10.02B 794M 776M 34.6B EV / Sales 2026 *
19.2x
EV / Sales 2027 * 12.6x
Free-Float
58.46%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week+6.47%
Current month+5.71%
1 month+6.47%
3 months+2.78%
6 months+87.34%
Current year+105.56%
1 week 0.67
Extreme 0.667
0.76
1 month 0.65
Extreme 0.65
0.78
Current year 0.33
Extreme 0.33
0.79
1 year 0.1
Extreme 0.095
0.79
3 years 0.08
Extreme 0.082
0.79
5 years 0.08
Extreme 0.082
1.5
10 years 0.08
Extreme 0.082
2.52
Manager TitleAgeSince
Chief Executive Officer - 2024-01-07
Director of Finance/CFO - 2023-04-02
Human Resources Officer - 2022-05-31
Director TitleAgeSince
Chairman 81 2014-06-12
Director/Board Member 55 2020-02-29
Director/Board Member - 2021-07-31
Date Insider Type Main position Quantity % Market Cap.
12/17/25 Free

Chief Executive Officer

6,525,939 1.5604%
10/21/25 Buy

Chairman

450,000 0.1076%
10/6/23 Expiration

Chief Executive Officer

514,918 0.1254%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%+6.47%+678.95%+236.36% 219M
+1.93%+3.85%+51.05%+166.24% 1,089B
+0.29%+6.43%+60.47%+52.87% 643B
+2.45%+2.77%+39.61%+74.48% 465B
-0.03%+11.16%+42.39%+36.55% 359B
+0.19%+4.56%+38.37%+43.91% 303B
+0.98%+3.21%+17.49%+17.20% 267B
-0.40%+4.76%-3.52%-38.71% 226B
+4.48%+7.33%+30.47%+66.31% 212B
+2.91%+3.10%+18.84%+74.76% 167B
Average +1.32%+5.21%+97.41%+73.00% 373.14B
Weighted average by Cap. +1.52%+5.14%+41.10%+79.99%

Financials

2026 *2027 *
Net sales 15.8M 11.02M 9.67M 9.01M 8.29M 15.53M 1.05B 107M 41.84M 522M 41.39M 40.49M 1.8B 24M 16.75M 14.7M 13.69M 12.59M 23.6M 1.6B 162M 63.55M 793M 62.87M 61.51M 2.74B
Net income -3.6M -2.51M -2.2M -2.05M -1.89M -3.54M -240M -24.35M -9.53M -119M -9.43M -9.23M -411M 100K 69.77K 61.23K 57.02K 52.45K 98.31K 6.67M 676K 265K 3.31M 262K 256K 11.42M
Net Debt -10.8M -7.54M -6.61M -6.16M -5.66M -10.62M -720M -73.06M -28.6M -357M -28.29M -27.68M -1.23B -10.8M -7.54M -6.61M -6.16M -5.66M -10.62M -720M -73.06M -28.6M -357M -28.29M -27.68M -1.23B
Logo Starpharma Holdings Limited
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Employees
40
Date Price Change Volume
26-07-29 A$0.7400 -0.67% 741,165
26-07-28 A$0.7450 +7.97% 2,155,614
26-07-27 A$0.6900 0.00% 2,104,924
26-07-24 A$0.6900 -0.72% 1,831,701
26-07-23 A$0.6950 0.00% 1,268,002
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.7450AUD
Average target price
0.8000AUD
Spread / Average Target
+7.38%

Annual profits - Rate of surprise